US Government Accountability Office. Drug shortages: FDA's ability to respond should be strengthened. December 15, 2011. http://www.gao.gov/assets/590/587000.pdf. Accessed February 1, 2013.
2.
GriffithMMGrossAESuttonSH. The impact of anti-infective drug shortages on hospitals in the United States: Trends and causes. Clin Infect Dis.2012;54(5):684–691.
3.
WoodcockJWosinskaM.Economic and technological drivers of generic sterile injectable drug shortages. Clin Pharmacol Ther.2013;93(2):170–176.
4.
Institute for Safe Medication Practices. Drug shortages: National survey reveals high level of frustration, low level of safety. ISMP Medication Safety Alert.2010;15(19):1–6.
5.
Hydromorphone IV [package insert]. Whippany, NJ: Halo Pharmaceuticals, Inc; 2009.
6.
Fentanyl citrate IV [package insert]. Lake Forest, IL: Hospira, Inc; 2008.
7.
Gray market, black heart: Pharmaceutical gray market finds a disturbing niche during the drug shortage crisis. ISMP Medication Safety Alert. August 25, 2011.
8.
DooleyKSullivanJA. Analysis of pharmaceutical product diversion and the gray market: Cheaper drugs, but at what cost?Health Care Law Mon.2010;2010(10):2–8.
9.
Centers for Disease Control and Prevention (CDC) Health Advisory. Meningitis and stroke associated with potentially contaminated product. http://emergency.cdc.gov/HAN/han00327.asp. Accessed February 1, 2013.
McLaughlinMMPentoneyZScheetzMH. Need for standardization in assessing impact of antibiotic shortages on patient outcomes. Am J Health Syst Pharm.2012;69(24):2129–2130.
12.
American Society of Health-System Pharmacists. ASHP Drug Product Shortages Management Resource Center. www.ashp.org/drugshortages. Accessed February 1, 2013
GriffithMMPatelJASuttonSH. Prospective approach to managing antimicrobial drug shortages. Infect Control Hosp Epidemiol.2012;33(7):745–752.
15.
FoxERBirtAJamesKBKokkoHSalversonSSoflinDL. ASHP Guidelines on Managing Drug Product Shortages in Hospitals and Health Systems. Am J Health Syst Pharm.2009;66(15):1399–1406.
